Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH MarketWatch In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an ... |
